2026 NPPES data Gynecologic Oncology Physician NPI 1215919477 M.D.
Verify on CMS →

ALIREZA ABIDI, M.D.

Gynecologic Oncology Physician in SACRAMENTO, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
637
Medicare Part D claims · 164 beneficiaries · Gynecologic Oncology Physician avg: 188
Generic prescribing
91%
generic claims · 9% brand-name · higher generic rates reduce patient out-of-pocket costs
What the federal data reveals: ALIREZA ABIDI, M.D. is a Gynecologic Oncology Physician ([object Object]) practicing in SACRAMENTO, California with a Medicare Part D prescribing footprint of 637 claims across 164 beneficiaries — 9% brand-name prescribing .

What stands out: ALIREZA ABIDI, M.D. filed 637 Medicare Part D claims in 2023 across SACRAMENTO, California. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

Board certification likely (heuristic — not verified)

ALIREZA ABIDI, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 2 hospital affiliations — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

ALIREZA ABIDI, M.D. at a glance

Quality data not reported

NPI registry status

Active

Issued 11/15/2005

NPI 1215919477

Primary specialty

Gynecologic Oncology Physician

Niche

1,360 US NPIs in this specialty

Medicare Part D claims

637 239% vs specialty avg

2023 prescription claims

Specialty avg: 188

Specialty distribution in California

How Gynecologic Oncology Physician compares to other specialties among California providers

California providers

Gynecologic Oncology Physician share within California

1. Gynecologic Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Gynecologic Oncology Physician share within California

Specialty board-certification context

Estimated specialty board-certified rate — Gynecologic Oncology Physician (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Gynecologic Oncology Physician ABMS/AOA estimate

Est. board-certified rate (Gynecologic Oncology Physician) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Gynecologic Oncology Physician) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

ALIREZA ABIDI, M.D. is a Gynecologic Oncology Physician provider practicing in SACRAMENTO, California, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: M.D.. NPI: 1215919477. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

ALIREZA ABIDI, M.D. appears in the CMS NPPES registry as a Gynecologic Oncology Physician provider holding M.D. credentials at 4860 Y ST, SACRAMENTO, CA, 95817, with a listed phone of (916) 734-6930. NPI 1215919477 was issued on 11/15/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what ABIDI most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 637 prescription claims written by this provider, covering 164 Medicare beneficiaries and totaling roughly $431K in drug spend, split 9% brand-name and 91% generic by claim count, with an opioid prescribing rate of 4.6%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Gynecologic Oncology Physician is a narrow specialty nationwide, with 1,360 enrolled providers across 49 states and an average of 188 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

4860 Y ST
SACRAMENTO, CA 95817

Provider Details

NPI 1215919477
Specialty Gynecologic Oncology Physician
Credentials M.D.
Gender Male
NPI Issued 11/15/2005

Hospital and facility affiliations

Facilities where ALIREZA ABIDI, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

LOS ANGELES HEMATOLOGY-ONCOLOGY MEDICAL GROUP
RIVERSIDE, CA
VALLEY OBSTETRICS AND GYNECOLOGY MEDICAL GROUP INC
COLTON, CA

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

License & disciplinary context — California MBC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to ALIREZA ABIDI, M.D.. To verify ALIREZA ABIDI, M.D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases

MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Generic-heavy

ALIREZA ABIDI, M.D. — brand share 9.0%
Specialty average (est.)

9% brand-name claims vs 91% generic, on 637 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

637
Total Claims
$431K
Total Drug Cost
164
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
1,125
Total Day Supply
27,668
Brand vs Generic
9% brand / 91% generic
Brand Drug Cost
$411K
Generic Drug Cost
$19K
Opioid Claims
29 (4.6% rate)
Antibiotic Claims
26

Patient Demographics

Average Patient Age
72.7 years
Avg HCC Risk Score
1.46

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Anastrozole
95
Estradiol
55
Ondansetron Hcl
36
Dexamethasone
35
Letrozole
34
Gabapentin
33
Lidocaine-Prilocaine
Lidocaine/Prilocaine
18
Zejula
Niraparib Tosylate
18
Clobetasol Propionate
17
Hydrocodone-Acetaminophen
Hydrocodone/Acetaminophen
14

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Gynecologic Oncology Physician Overview

How ALIREZA ABIDI, M.D. fits within the Gynecologic Oncology Physician landscape nationally.

1,360
Gynecologic Oncology Physician Providers in US
49
States with Gynecologic Oncology Physician
188
Avg Claims per Provider

ALIREZA ABIDI, M.D.'s 637 claims are above the specialty average of 188.

Nearby Gynecologic Oncology Physician Providers in California

Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as ABIDI.

Compare Gynecologic Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is ALIREZA ABIDI, M.D.'s specialty?
ALIREZA ABIDI, M.D. specializes in Gynecologic Oncology Physician and practices in SACRAMENTO, California. Credentials: M.D..
How much does ALIREZA ABIDI, M.D. prescribe under Medicare Part D?
In 2023, ALIREZA ABIDI, M.D. wrote 637 Medicare Part D claims totaling $431K in drug costs for 164 beneficiaries.
Where is ALIREZA ABIDI, M.D. located?
ALIREZA ABIDI, M.D. is located at 4860 Y ST, SACRAMENTO, CA, 95817. Phone: (916) 734-6930.
What is ALIREZA ABIDI, M.D.'s NPI number?
ALIREZA ABIDI, M.D.'s National Provider Identifier (NPI) is 1215919477, issued on 11/15/2005.
Does ALIREZA ABIDI, M.D. prescribe more brand-name or generic drugs?
ALIREZA ABIDI, M.D.'s prescribing is 9% brand-name and 91% generic drugs by claim count, with $411K in brand drug costs.
Does ALIREZA ABIDI, M.D. prescribe opioids?
Yes, ALIREZA ABIDI, M.D. had 29 opioid claims in 2023 with an opioid prescribing rate of 4.6%.
How many Gynecologic Oncology Physician providers are there in the US?
There are 1,360 Gynecologic Oncology Physician providers across 49 states in the US. The average Gynecologic Oncology Physician provider writes 188 Medicare Part D claims per year.
What drugs does ALIREZA ABIDI, M.D. prescribe most often?
Based on 2023 Medicare Part D data, ALIREZA ABIDI, M.D.'s most frequently prescribed drugs include Anastrozole, Estradiol, Ondansetron Hcl. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does ALIREZA ABIDI, M.D. accept Medicare?
ALIREZA ABIDI, M.D. appears in CMS Medicare data with 637 Part D claims and 164 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify ALIREZA ABIDI, M.D.'s credentials?
ALIREZA ABIDI, M.D.'s NPI is 1215919477 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology